Multivariate analysis identified cladribine as an independent prognostic factor for longer survival for IDH2+ patients in both the entire NK-AML cohort and the NPM1−/FLT3-ITD− subgroup. This evidence concerns the gene IDH2 and acute myeloid leukemia.